Alexander Leandros Lazarides, MD, discusses some of the current challenges in moving the field forward in osteosarcoma.
Alexander Leandros Lazarides, MD, resident at Duke University Medical Center, discusses some of the current challenges in moving the field forward in osteosarcoma.
Since the use of chemotherapy in the 1970s, few advancements have been made in this field, says Lazarides.
Although osteosarcoma has a bimodal distribution, it disproportionally affects a pediatric population, explains Lazarides.
Additionally, the existing model for osteosarcoma may not be sufficient as the disease is highly heterogeneous, says Lazarides. As such, targeting a specific pathway has proven difficult.
The identification of novel agents and developing a more efficient drug discovery model is critical to push the field forward, concludes Lazarides.